Oncorus Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0261
- Today's High:
- $0.0262
- Open Price:
- $0.0261
- 52W Low:
- $0.0211
- 52W High:
- $1.38
- Prev. Close:
- $0.0301
- Volume:
- 5559
Company Statistics
- Market Cap.:
- $913321
- Book Value:
- 1.193
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -32.24%
- Return on Equity TTM:
- -124.56%
Company Profile
Oncorus Inc had its IPO on 2020-10-02 under the ticker symbol ONCR.
The company operates in the Healthcare sector and Biotechnology industry. Oncorus Inc has a staff strength of 64 employees.
Stock update
Shares of Oncorus Inc opened at $0.03 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.03 - $0.03, and closed at $0.03.
This is a -12.96% slip from the previous day's closing price.
A total volume of 5,559 shares were traded at the close of the day’s session.
In the last one week, shares of Oncorus Inc have slipped by -25.14%.
Oncorus Inc's Key Ratios
Oncorus Inc has a market cap of $913321, indicating a price to book ratio of 0.1266 and a price to sales ratio of 0.
In the last 12-months Oncorus Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-69700000. The EBITDA ratio measures Oncorus Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Oncorus Inc’s operating margin was 0% while its return on assets stood at -32.24% with a return of equity of -124.56%.
In Q1, Oncorus Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Oncorus Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Oncorus Inc’s profitability.
Oncorus Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0391. Its price to sales ratio in the trailing 12-months stood at 0.
Oncorus Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $109.75 million
- Total Liabilities
- $31.11 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $73000
- Dividend Payout Ratio
- 0%
Oncorus Inc ended 2024 with $109.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $109.75 million while shareholder equity stood at $31.12 million.
Oncorus Inc ended 2024 with $0 in deferred long-term liabilities, $31.11 million in other current liabilities, 3000.00 in common stock, $-302908000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $21.22 million and cash and short-term investments were $44.98 million. The company’s total short-term debt was $21,725,000 while long-term debt stood at $0.
Oncorus Inc’s total current assets stands at $46.67 million while long-term investments were $0 and short-term investments were $23.77 million. Its net receivables were $0 compared to accounts payable of $2.76 million and inventory worth $0.
In 2024, Oncorus Inc's operating cash flow was $0 while its capital expenditure stood at $73000.
Comparatively, Oncorus Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.03
- 52-Week High
- $1.38
- 52-Week Low
- $0.0211
- Analyst Target Price
- $5
Oncorus Inc stock is currently trading at $0.03 per share. It touched a 52-week high of $1.38 and a 52-week low of $1.38. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $0.04 and 200-day moving average was $0.25 The short ratio stood at 0.74 indicating a short percent outstanding of 0%.
Around 1341.5% of the company’s stock are held by insiders while 4172.2% are held by institutions.
Frequently Asked Questions About Oncorus Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.